{"id":"W3032169917","doi":"10.1200/jco.2020.38.15_suppl.5022","title":"Phase II trial of atezolizumab in BCG-unresponsive non-muscle invasive bladder cancer: SWOG S1605 (NCT #02844816).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":55,"is_retracted":false,"has_abstract":true,"ca_institutions":"McGill University Health Centre; University of British Columbia","funders":"National Institutes of Health","keywords":"Medicine; Atezolizumab; Concomitant; Bladder cancer; Clinical endpoint; Cystectomy; Urology; Cystoscopy; Internal medicine; Oncology; Surgery; Cancer; Clinical trial; Immunotherapy; Urinary system; Pembrolizumab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002077774,0.001104244,0.001189187,0.00030344,0.0002712389,0.0005925089,0.0007160113,0.001240238,0.008674542],"category_scores_gemma":[0.0009526309,0.0003805237,0.0008632335,0.0003006143,0.0005937118,0.0004996982,0.0004074026,0.002505929,0.001475653],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005393046,"about_ca_system_score_gemma":0.001639458,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005721168,"about_ca_topic_score_gemma":0.001912761,"domain_scores_codex":[0.9996264,0.0002175416,0.00002071687,0.00004273837,0.0000302065,0.00006236262],"domain_scores_gemma":[0.9994279,0.00008787309,0.0001417952,0.00004289369,0.00004074695,0.000258825],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7768218,0.04804286,0.008536588,0.00199674,0.001152019,0.0002907175,0.0002714873,0.001729851,0.03161203,0.0005627411,0.01352322,0.1154601],"study_design_scores_gemma":[0.6967851,0.2874103,0.008097005,0.00006059317,0.0002791068,0.0002487741,0.0000423291,0.000929851,0.002140184,0.0001803378,0.003811974,0.00001456799],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9769126,0.003514214,0.001084466,0.001115296,0.0003106422,0.008067741,0.003704033,0.0001883603,0.005102642],"genre_scores_gemma":[0.9672095,0.002283695,0.002621843,0.002352112,0.0002720972,0.007677965,0.008185199,0.00004535688,0.009352253],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.008674542,"threshold_uncertainty_score":0.02901918,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1623159495672049,"score_gpt":0.4948129775006119,"score_spread":0.332497027933407,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}